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Summary.3 Objective: To investigate in how far successful
simulation of a thrombin generation (TG) curve gives infor-
mation about the underlying biochemical reaction mechan-
ism. Results: The large majority of TG curves do not contain
more information than can be expressed by four parameters. A
limited kinetic mechanism of six reactions, comprising proteo-
lytic activation of factor (F) X and FII, feedback activation of
FV, a cofactor function of FVa and thrombin inactivation by
antithrombin can simulate any TG curve in a number of
different ways. The information content of a TG curve is thus
much smaller than the information required to describe a
physiologically realistic reaction scheme of TG Consequently,
much of the input information is irrelevant for the output.
FVIII deficiency or activation of protein C can, for example, be
simulated by a reaction mechanism in which these factors do
not occur. Conclusion: Amodel that comprises not more than
six reactions can simulate the same TG curve in a number of
possible ways. The possibilities increase exponentially as the
model grows more realistic. Successful simulation of experi-
mental data therefore does not validate the underlying
assumptions. A fortiori, simulation that is not checked against
experimental data lacks any probative force. Simulation can be
of use, however, to detect mistaken hypotheses and for
parameter estimation in systems with fewer than five free
parameters.
Keywords: mathematical simulation, model discrimination,
thrombin generation.
Introduction
One of the traditional approaches to the study of the
coagulation system is monitoring the course of activated
factors in clotting blood or plasma [1]. Notably the rise and fall
of thrombin in clotting blood, that is, the thrombin generation
(TG) curve is of renewed interest [2,3]. Computer simulation
can be used to link observed time courses to the underlying
reaction mechanism [4,5].
After developing suitable numerical methods [6], we intro-
duced simulation as a tool in the analysis of the web of
coagulation reactions in 1991. We obtained near-perfect
similarities between simulated reaction mechanisms and the
outcome of real experiments [4]. Nevertheless, we have
published sparingly on this subject because we soon realized
that it is possible to postulate a large variety of mechanisms all
of which can explain the same experimental results. This is not
surprising because the information required as an input for a
plausible reaction mechanism of TG is much larger than the
information that characterizes the output. Consequently, much
information must be irrelevant in the process of simulation and
variations in such irrelevant information cannot be seen in the
outcome.
In enzyme kinetics (see e.g. [7]) even the most simple model
(E + S « C fi E + P) contains three reaction constants,
whereas only two experimental parameters,Km and kcat, can be
obtained from initial rate measurements. When simulating this
system one can postulate any value for the backward constant
(even zero) as long as the three constants together lead to the
experimentally observed values of Km and kcat. It also is
standard knowledge that, on basis of Km and kcat, one cannot
distinguish between this simple model and a large variety of
more complicated ones; that is, it makes no sense to postulate
more reactions than necessary to explain the experimental
findings.
In the case of the coagulation reactions this leads to the
question: if we include the available pre-existing knowledge, do
we postulate more reactions and parameters than necessary to
explain the TG curve? If yes, the excess information does not
contribute to the outcome and can be arbitrarily varied.
If a simulated curve does not mimic the experimental
data within the limits of experimental error, one can be sure
that the postulated mechanism and/or constants are not
correct. The inverse is not true however; a fitting simulation
does not validate the underlying assumptions. As soon as
more information is entered in the simulation than required
to define the TG curve it becomes possible that alternative
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mechanisms or constants could simulate the data equally
well. The larger the number of postulated reaction constants
compared to the number of parameters in the experimental
output, the more degrees of freedom and the less probative
force of a fitting simulation.
The recent increase in the use of numerical simulation
(experiments in silico, e.g. [8–18]) has led us to assess this
global reasoning quantitatively. To this end, we first show that
four independent parameters can be experimentally obtained
from a TG curve. Then we show that a web of only six
reactions simulate any TG curve. Any plasmatic clotting
mechanism is much larger. Consequently unequivocal attribu-
tion of one set of plausible concentrations and reaction
constants to one experimental TG curve obtained in plasma
is impossible.
Materials and methods
Platelet poor pooled plasma (PPP) was prepared as described
previously [19] from blood taken on 0.1 volume of 0.13 M
sodiumcitrate fromat least 12apparentlyhealthydonors. Itwas
stored at )80 C for < 3 months. As a source of recombinant
tissue factor (rTF) we used Innovin (Dade-Behring, Marburg,
Germany). Procoagulant phospholipids containing 60 mole%
dioleoyl PC, 20 mole% dioleoyl PS and 20 mole% dioleoyl PE
were prepared as described earlier [20]. Thrombomodulin (TM)
was soluble recombinant TM, a gift of Asahi,4 Japan. Activated
protein C (APC) was a gift of Regnault (INSERM unit 284,
Nancy, France), prepared according toRegnault et al. [21]. The
samplesofhemophiliacplasmaafter infusionofa factor (F)VIII
concentrate were donated byH.M.Van denBerg, VanCreveld
kliniek, Utrecht, the Netherlands. TG curves were obtained via
calibrated automated thrombinography as described in detail
previously [22]. Briefly, the reaction mixtures (120 lL) con-
tained in all cases citrated PPP diluted 2:3, 5 pM rTF, 4 lM PL,
16.7 mM CaCl2, 417 lM Z-GGR-AMC and, where indicated,
6 nMAPC or 6 nM TM. Each experiment was carried out in 16
replicates.
Average curves and limits of experimental accuracy
To obtain an average curve from a number of replicate curves,
we first measured the lag time of each individual curve,
arbitrarily defined as the moment that the thrombin concen-
tration stayed above the 10 nM level, and determined the
average lag-time (tlag) and its standard deviation (SD). Then we
lined up the curves at the average lag time and determined the
average thrombin concentration (Tt) at each time point (t) and
its SD. Around every experimental point of the average curve,
the SDs along the time and the concentration axis were plotted.
We considered a fit acceptable if the simulated thrombin
concentration did not at any time-point differ more than 1 SD
from the average Tt. To visualize the goodness of fit of
simulated curves we plotted the difference between the
observed and the calculated values (the residuals) and com-
pared it to the SD (Figs 1 and 4, lower panels).
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Mathematical procedures
In the experimental section we define the W-function, an
explicit four-parameter function that fits to experimental TG
curves. The procedure for fitting a function to experimental
data is incorporated in a number of commercially available
programs. We used that available from SIGMAPLOT5 or self-
written software. The mathematical background of the fitting
[23–25] is given in the annexe. There we also show the
mathematical method to determine the maximal number of
parameters that can be reliably computed from a set of
experimental data. If more than this maximal number of
parameters is used for optimization, the model starts to fit to
arbitrary experimental noise. The additional freedom intro-
duced by adding an extra parameter cannot be used to decrease
the discrepancy betweenmodel and experiments below the level
that is inevitably determined by the experimental error. In fact,
the additional freedom would introduce manifold possible
models of indistinguishable validity.
Results and discussion
The information content of the TG curve; the W-function
We determined TG curves in 16 replicates for normal PPP in
the presence and absence of APC or TM, and calculated the
average curve and the SEM in every point (Fig. 1, upper
panels). These curves could be fitted to an explicit function with
four parameters:
T ¼ Wða; b; c; t0; tÞ ¼ abc ebcðt t0Þ  ðebðt t0Þ  1Þðc 1Þ
(where T ¼ thrombin concentration, t is time and t0 a, b, c are
constants [>0]).
This function, called the W-function, could fit any experi-
mentalTGcurve thatwe testedwithin the limits of experimental
error. Not only the curves of Fig. 1 but also a series of curves in
whichoneofFII,FV,FVII,FXandFXIwaspresent in limiting
concentration [26] (results not shown) and curves obtained at 10
time points after injection of a dose of 50 IU kg)1 of FVIII in a
hemophilic patient (see further [27]). In Fig. 2, four of these
curves are shown, the other time points, and a similar series in
another hemophilic patient showed similar results.
The W-function does not reflect an underlying model of
chemical reaction, as does, for example, the hyperbola of
classical enzyme kinetics. It remains perfectly possible that TG
curves exist that cannot be fitted to the W-function. We found
such curves, for example, when measuring TG in platelet rich
plasma. They could always be fitted to the sum of two W-
functions, that is, with eight parameters (results not shown).
For the development of our argument, it does not matter
whether four or eight parameters describe the TG curve, as
both figures are considerably smaller than the number of
parameters (concentrations and constants) that describe the
chemistry of TG.
Computation of the sensitivity matrix according to Golub
and Ortega, and Walter and Pronzato [24,25], applied to the
data of Figs 1 and 2, showed that the singular values of the four
parameters varied by three orders of magnitude (e.g. 8054, 543,
182, and 21). The first value is 400-fold as big as the last, which
indicates that a random deviation of the data that is so small as
to cause a 0.1% variation in the best determined parameter can
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Fig. 2. Fitting of theW-function to TG curves in hemophilia. 50 IU of
factor VIII (FVIII) per kg body weight were injected into a severe
hemophilic patient [see 27] and TG curves were determined at t ¼ 0, 0.25,
0.5, 1, 3, 5, 7, 12, 24, 30, 48 and 60 h. For clarity, only the t ¼ 0, 1, 24 and
60 h curves are shown. Black lines: measured data, red lines fitted curves.
Similar fits were obtained for the curves not shown.
Fig. 1. Fitting of the W function to thrombin generation (TG) curves.
Upper panels: the mean course of thrombin concentration (open circles,
n ¼ 16) and the ±1 SD confidence area (black lines, see Materials and
methods). Red line: fit of the experimental data by theW-function. Lower
panels: ±SD per time point (black lines) and the difference between the
fitted and the experimental curves (red line). From left to right: NPP
without any additions (t0 ¼ 2.474, a ¼ 1657, b ¼ 0.478 and c ¼ 7.69);
aPC added (t0 ¼ 2.688, a ¼ 465, b ¼ 0.477 c ¼ 11.6); TM added
(t0 ¼ 3.740, a ¼ 735, b ¼ 0.497 and c ¼ 3.631).
Factor V
Kd
5. kdec
TAT
Factor Xa + Factor VaFactor X
Factor VIIa
(trigger) Prothrombin Thrombin
+
Anthithrombin
Prothrombinase
3. Km, kcat
4. Km, kcat
2. Km, kcat1. Km, kcat
Fig. 3. A minimal model for TG in plasma.
Simulation limits of the clotting system 3
 2006 International Society on Thrombosis and Haemostasis
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
also be accommodated by a 40% change in the least well
determined one.
The minimal mechanism
The link between the experimental curves and a reaction
mechanism cannot be calculated analytically and must be
approached by numerical simulation. As discussed in the
introduction, the limits of meaningful simulation are set by the
smallest chemical mechanism that can fit a TG curve. This
appeared to be a set of six reactions (Fig. 3), quantitatively
defined by the initial concentration of five proteins, eight
kinetic constants and a decay constant, that is, by 14
parameters. Upon simulation, the reaction scheme of Fig. 3
can fit the TG curves of Figs 1 and 2 as well as any other TG
curve that we tried (Figs 4 and 5). Readers can find a program
at http://www.thrombin.com to try this for themselves. Fig. 4
shows that the effects of added APC and TM could be
simulated without introducing APC- or TM-dependent reac-
tions. In Fig. 5 it is seen that variation of FVIII is readily
simulated by a reaction scheme, in which FVIII does not play a
role (Fig. 5).Minor adaptations in the reaction constants of the
FV activation reaction and the kcat of the prothrombinase
reaction, together with large changes in the prothrombin
concentration, are sufficient to fit the experimental curves. It
should be noted that we purposely changed the prothrombin
concentration to values that we know to be false, in order to
stress the fact that near to perfect simulation still does not prove
the underlying assumptions to be correct.
Not only known reactants such as FVIII, FIX and TFPI are
missing from this scheme, but also phospholipid-protein
interactions are not included. It is simply assumed that FXa
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Fig. 4. Simulation of TG-curves with the minimal reaction mechanism.
6Upper panels: the mean course of thrombin concentration (open circles,
n ¼ 16) and the ±1 SD confidence area (black lines, see Materials and
methods). Red line: fit of the experimental data by theW-function. Lower
panels: ±SD per time point (black lines) and the difference between the
fitted and the experimental curves (red line). From left to right: NPP
without any additions (t0 ¼ 2.474, a ¼ 1657, b ¼ 0.478 and c ¼ 7.69);
aPC added (t0 ¼ 2.688, a ¼ 465, b ¼ 0.477 c ¼ 11.6); TM added (t0 ¼
3.740, a ¼ 735, b ¼ 0.497 and c ¼ 3.631). Three sets of parameters were
used to obtain the fit. The fixed parameters were: Trigger: 15 pM; Factor X
(FX) activation by trigger: S ¼ 30 nM, Km ¼ 10 nM, kcat ¼ 4.5 s)1; Pro-
thrombin activation by Xa: Km ¼ 5 nM; Factor V (FV) activation by
thrombin: Km ¼ 40 nM; Kd of prothrombinase complex (PTase): 60 pM;
Prothrombin activation by PTase: Km: 450 nM; Thrombin inactivation by
AT: AT ¼ 2.5 lM. Variable reaction parameters:
Left Middle Right
FV (lM) 4 5.5 5
Prothrombin (lM) 1.25 0.276 0.5
kcat FII by Xa (s
)1) 0.002 0.0023 0.0014
kcat FV by FIIa (s
)1) 0.018 0.005 0.04
kcat FII by PTase (s
)1) 6.2 8 6.2
kcat FIIa inact. by AT (M.s)
)1 14260 7843 9270
Because in practice the fluorogenic substrate Z-GGR-AMC is present,
its effect on the TG is taken into account. The used Km was 440 lM and
the kcat 1.33 s
)1.
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and FVa form a prothrombinase complex (Kd 60 pM) that has
a lower Km and a higher kcat than FXa alone. This shows that
in a realistic reaction scheme there is much more information
than needed to simulate a TG curve. In reality, the number of
reactions in the mechanism is at least 24, and needs at least 54
parameters (concentrations and kinetic constants) [14].
Does the minimal reaction mechanism allow one or more
solutions?
The next question is whether the fits obtained with the
oversimplified reaction scheme are unique. Figure 6 shows
two curves that are indistinguishable from each other and
yet are obtained by different sets of parameters. A multi-
plicity of such sets is easily found. It suffices to replace one
of the parameters by an arbitrary value of the same order of
magnitude and adapt the others always to obtain a fitting
curve. This shows that a curve, indistinguishable from an
experimental result, can be obtained in a variety of ways,
and that even the simplest possible reaction scheme could
not be used to obtain an unequivocal simulation of a real
TG curve.
We conclude that the technique of simulation is unable to
distinguish between a large number of different possibilities.
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Fig. 5. Simulation of TG curves in severe hemophilia by the minimal reaction mechanism. 50 IU7 of FVIII per kg body weight were injected into a severe
hemophilic patient [see 27] and TG curves were determined at t ¼ 0, 0.25, 0.5, 1, 3, 5, 7, 12, 24, 30, 48, and 60 h. For clarity, only the t ¼ 0, 1, 24 and 60 h
curves are shown. Black lines: measured data, red lines fitted curves. Similar fits were obtained for the curves not shown. The fixed parameters were:
Trigger: 10 pM; FX activation by trigger: S ¼ 10.5 nM, Km ¼ 10 nM, kcat ¼ 4.5 s)1; Prothrombin activation by Xa: S: Km ¼ 5 nM, kcat ¼ 0.0005 s)1; Kd
of prothrombinase complex ¼ 60 pM; FV activation by thrombin: S: 5 nM,Km ¼ 40 nM. The variable parameters are given in the table below. Also in this
case the effect of the fluorogenic substrate was taken into account.
Variable reaction parameters:
Top left Top right Bottom left Bottom right
Prothrombin (lM) 0.12 1.37 0.85 0.42
Antithrombin (lM) 1.8 2.2 1.8 1.8
kcat Factor (F) Va by FIIa (s
)1) 0.12 0.0055 0.012 0.09
Km PTase (nM) 95 450 300 95
kcat PTase (s
)1) 0.2 10 3.1 0.5
kcat FIIa inact. by AT (s
)1) 7490 14260 12840 7490
Simulation limits of the clotting system 5
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Among these there will be many, such as our minimal scheme,
that can be discarded on the basis of existing scientific evidence.
If, however, among the realistic possibilities there are two or
more that are equally likely, simulation will not be able to
identify the correct one.
The introduction of parameters from other experiments
One can decrease the number of possible interpretations by
introducing parameters that are independently obtained
(external parameters). The initial concentrations of, for
example, all the clotting factors can be readily determined. In
experiments where a reaction sequence is reconstituted from
isolated factors one can determine the reaction constants in
independent experiments under conditions closely similar to
those of the TG experiment [28]. Such systems have the
additional advantage that one can be sure about the reaction
mechanism and that no fibrin is formed, so that diffusional
transport will not play a role (see below).
In plasma the decay constant of thrombin can be estimated
directly [29] but others, such as, for example, the kinetic
constants of prothrombinase cannot be determined under the
conditions prevailing in plasma. Values obtained in purified
systems [20,30–32] differ up to 100-fold and it remains
unknown which, if any, apply in plasma, because kinetic
constants are strongly dependent upon the reaction
conditions.
In plasma, not only the reaction constants but even the
reaction mechanism itself is not known with certainty. The
anticoagulant role of FV and the direct inhibitory role of
protein S or the role of protein Z are examples of
complications that went unrecognized until quite recently
[33,34]. The precise role of minor players such as b2-
glycoprotein 1 [35], annexin V [36,37] and other phosphol-
ipid binding proteins remains open, and it seems prob-
able that among the 1175 known plasma proteins [38] one
or more could play an as yet unrecognized role. A
further complication is that in the presence of fibrin, the
reaction velocity is co-determined by diffusion and there-
fore not adequately described by chemical processes alone
[39].
In view of these uncertainties concerning: (i) the reaction
constants; (ii) the reaction mechanism; and (iii) the role of
diffusional transport, one cannot claim a priori, the validity of
the assumptions on which a simulation is based. Neither can
one prove it a posteriori because, as we have seen above, a
successful simulation can easily result from incorrect assump-
tions. The trap to be avoided here is the circular argument in
which the acceptability of the simulated curve is thought to
follow from the correctness of the assumed reactionmechanism
and parameters, and the correctness of the assumptions from
the acceptability of the fit.
In the present state of knowledge no simulation is better than
the conjectures about themechanism and the parameters [9,10].
In view of the reasonable doubt about the one as well as about
the other, it seems wiser not to use simulation for clinical
diagnosis and epidemiology but rather rely on measurement of
TG [3,40].
Simulation of a system as complicated as plasmatic throm-
bin formation cannot be proven to be correct but can be proven
to be false when it does not to fit to experimental data. In the
literature (e.g. [8–18]) one occasionally encounters simulations
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Fig. 6. Simulation of the TG curve with the minimal reaction mechanism
and two sets of constants8 . To the experimental data of the mean TG curve
of Fig. 1, first panel, two simulated TG curves were fitted using the min-
imal model with two different sets of constants. Fixed reaction parameters:
FX activation by trigger: S ¼ 30 nM, Km ¼ 10 nM, kcat ¼ 4.5 s)1; Pro-
thrombin activation by Xa: Km ¼ 5 nM, kcat ¼ 0.002 s)1; FV activation
by thrombin: Km ¼ 40 nM.
Variable reaction parameters:
Left Right
Trigger (nM) 0.015 0.0085
Factor (F) V (nM) 5 80
kcat FV activation by FIIa (s
)1) 0.018 0.0011
Prothrombin (lM) 1.35 0.95
Km PTase (nM) 450 250
kcatPTase (s
)1) 6.2 8.0
Antithrombin (lM) 2.5 2
kdec thrombin inactivation by AT (M.s)
)1 14260 16830
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that are not quantitatively compared to experimental data.
Such simulations can neither be verified nor disproved
(falsified) and therefore do not allow scientifically valid
conclusions [41]. When the restraint of comparison to experi-
mental observations is abandoned, simulation degenerates into
an exercise with the reality content of every other computer
game.
Requirements for successful use of simulation techniques
To escape the ambiguities of the simulation of large systems in
plasma, one has to reduce the number of unknown parameters
to a minimum without introducing parameters from incom-
parable experiments. In the first place one can restrict the
reaction mechanism to a size that is amenable to simulation
with aminimal degree of uncertainty; for example by triggering
TG in plasma with the FX activating enzyme of Russell’s viper
venom [42]. The initial clotting factor concentrations can be
determined independently as well as the kinetic constants of
thrombin decay [29]. This reduces the number of free param-
eters to nine.With the aid of parameter fitting programs the full
variety of solutions can be found [43]. Then experiments can be
repeatedwith varying concentrations of one clotting factor (e.g.
prothrombin) and from the possible solutions those can be
selected in which the reaction constants do not vary as the
factor concentration changes. Once such a small system is
quantitatively well defined, a stepwise increase of complexity
may in the end lead to exact simulation of the complete system.
We recall, however, that our conclusions pertain to homogen-
eous closed systems, that is, plasma in a test tube. Open, non-
homogeneous systems such as TG in vivo are much more
complicated.
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Appendix: mathematical procedures
The mathematical technique behind the fitting procedure is
the following: One starts with an arbitrary guess of the best
parameters (the vector P0,), that is, in our case the four
parameters of the W function (see below). Then a correction
vector is calculated by solution of the linear system of
equations (J(p)TJ(p))DP ¼ J(p)T r, where r is the residue,
that is, the difference between the measured and the
calculated value at each time point. The new and better
estimate for the parameters then is P0 + DP. This procedure
is repeated until convergence. The goodness of fit is expressed
by
s ¼ sqrðt¼ 1
XN
ððriðpÞÞ2Þ=NÞ:
This value should be of the order of the experimental error.
If it is larger, the fit is not good enough, if it is much smaller, the
fit determines parameters that cannot be attributed a meaning
and thus are unnecessary.
To understand the computation of the minimal number of
meaningful parameters, some knowledge of multivariate sta-
tistics is needed, as can be found e.g. in Anderson [23]. The
technique itself is based on References [24] and [25].
Denoting the model by W (p, t), where t (time) is the
independent variable and the vector p contains theM available
parameters, the sensitivity matrix J(p) is defined as
JðpÞ ¼ ðJðpÞÞi:j ¼ ðdWðpj; tiÞ=dpjÞ:
Here t1, t2, ……, tN are the values of the independent
variable for which themeasurements were made. Clearly J(p) is
an N · M-matrix with N > M, because more measurements
should be available than free parameters in the model.
The size of the singular values of the matrix J(p) determines
the number of free parameters that can be computed from the
available measurements. The singular values r1 ‡ r2 ‡ … ‡ 0
are the square roots of the eigenvalues of the M · M-matrix
J(p) TJ(p).
The number of parameters that can be determined from the
available data is equal to the number of singular values that is
larger than r1s, where 100 s is the percentage of the
experimental error in the measurements.
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